MedTrace Logo

Ultralong-segment Barrett's Esophagus: Towards a Capsule-sponge Surveillance Strategy

NCT06720636 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 137

Last updated 2025-08-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the Endosign capsule sponge test as a novel surveillance method in patients with an ultralong-segment Barrett's esophagus.

Conditions

  • Barrett Esophagus

Interventions

DEVICE

EndoSign

The EndoSign cell collection device is a non-endoscopic capsule sponge device used to collect pan-esophageal samples. The Endosign procedure consists of an expandable, spherical mesh, which is attached to a string and contained within a soluble capsule. Seven minutes after swallowing (once the capsule has dissolved), the spherical mesh, which measures around 3cm in diameter is retrieved by pulling on the string. Upon retrieval the capsule-sponge scrapes against the surface of the top of the stomach and esophagus and collects epithelial cells. The capsule-sponge sample is then placed into a preservative fluid and the specimen is processed for molecular tests.

Sponsors & Collaborators

Principal Investigators

  • Judith Honing, MSc, PhD · Erasmus Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-03
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06720636 on ClinicalTrials.gov